Xponance Inc. Has $1.30 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Xponance Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,018 shares of the medical research company’s stock after selling 251 shares during the quarter. Xponance Inc.’s holdings in Charles River Laboratories International were worth $1,296,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CRL. Cibc World Markets Corp raised its position in shares of Charles River Laboratories International by 16.1% in the fourth quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 1,124 shares during the period. Hilton Capital Management LLC raised its position in shares of Charles River Laboratories International by 5.0% in the fourth quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company’s stock valued at $1,484,000 after purchasing an additional 380 shares during the period. Impact Capital Partners LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $422,000. Truvestments Capital LLC raised its position in shares of Charles River Laboratories International by 6.4% in the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 155 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of Charles River Laboratories International by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 155 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on CRL. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Bank of America dropped their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Trading Up 1.2 %

Shares of Charles River Laboratories International stock opened at $167.29 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $273.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company’s fifty day moving average price is $166.11 and its two-hundred day moving average price is $183.71. The firm has a market capitalization of $8.55 billion, a PE ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the company earned $2.46 EPS. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In other news, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Birgit Girshick bought 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).